Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929226 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
A Phase 1 study, sponsored by Elusys Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
NCT01929226: Completed Phase 1 study, sponsored by Elusys Therapeutics.
NCT01929226 is a Phase 1 study that has completed, run by Elusys Therapeutics. The registered enrollment target is 280 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (367% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01929226, a Phase 1 study, has completed, sponsored by Elusys Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous (IV) dose of ETI-204 in adult volunteers.
Primary Outcome
Safety was assessed for all subjects in the safety population by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, skin assessments, infusion site assessments, and adverse events.
Interventions
- OTHER Placebo
- BIOLOGICAL ETI-204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2013-07-09 |
| Est. Completion | 2013-11-29 |
| Phase | Phase 1 |
What the finished NCT01929226 record still lists
NCT01929226 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (367% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01929226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01929226 about?
NCT01929226 is a clinical study titled "Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers". To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous (IV) dose of ETI-204 in adult volunteers.
What is the current status of trial NCT01929226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2013-07-09. Estimated completion is 2013-11-29.
What interventions are being tested in trial NCT01929226?
The interventions under investigation include: Placebo (OTHER), ETI-204 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01929226?
This trial is sponsored by Elusys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01929226's enrollment target sits among peer trials
280 141st of 2000 higher than 1,855 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI